ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1228

Involvement of the IFN-Õ Pathway in a Patient with Candle Syndrome Carrying  a Novel Variant of PSMB8 Gene

Antonella Insalaco1, Giusi Prencipe2, Manuela Pardeo3, Virginia Messia3, Andrea Masotti3, Cristina de Min4, Claudia Bracaglia2, Rebecca Nicolai3, Ivan Caiello2 and Fabrizio De Benedetti Sr.2, 1Department of Pediatric Medicine,, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3Division of Rheumatology, Department of Pediatric Medicine, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy, 4Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease and interferons

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome is a newly described autoinflammatory disease. We describe clinical phenotype and cytokine profile of our patient. Methods: A 10 years-old young girl presented at 10 months of age with recurrent fever, hepatosplenomegaly and nodular erythematous skin lesions; she progressively developed lypodistrophy, arthralgia, arthritis and edema of eyelids. Skin biopsy showed features of lobular panniculitis. Laboratory tests showed persistent elevated acute phase reactants with anemia, recurrent leucopenia, thrombocytopenia and hypogammglobulinemia. Immunological and cytogenetic studies performed on bone marrow were normal. Subsequently, the patient developed nephrotic syndrome. Renal biopsy revealed a minimal change glomerulopathy responsive to high-dose glucocorticoid. Response to hydroxychlorochine, colchicine, cyclosporine-A, and anakinra was unsatisfactory. Complete sequencing of TNFRSF1A and MVK genes showed no mutations. Analysis of the PSMB8 (proteasome subunit β type 8) gene revealed the presence of c.220A>T p.(T74S) variant in heterozygotic status that has never been reported before. In order to assess the dysregulated inflammatory response, we evaluated the cytokine profile in patient’s sera using the Luminex multiplexing assay. Whole blood RNA analysis was also performed using a human immune array (TaqMan® Human Immune Array from Applied Biosystems), containing 92 genes typically involved in the immune response. Results: Serum samples (n=4) were collected during the last two years. We found high levels of IFNγ (mean ± S.D.: 115.3 pg/ml ± 64.21), of IFNγ inducible protein 10 (IP-10, also called CXCL10) (1641± 892.5 pg/ml) and of IFNγ inducible protein 9 (IP-9, also called CXCL11) (582.9± 335.6 pg/ml) and especially of CXCL9, also known as monokine induced by γ-interferon (MIG) (18161± 6405 pg/ml), compared to healthy controls or pediatric patients with sJIA during active disease. Two whole blood RNA samples collected from our Candle patient were compared to 6 whole blood RNA samples collected from healthy controls comparable for age. We obtained results consistent with those obtained by serum cytokine measurement: IFNγ, CXCL10 and CXCL11 mRNA expression were significantly increased compared to healthy controls (1.88, 32.7 and 4.1 fold higher respectively). We also found that the expression of the HLA-DRB1, a gene whose expression is known to be induced by IFNγ, was markedly upregulated (> 100.000 fold increase) compared to healthy controls. Conclusion: we describe a typical CANDLE clinical phenotype in the absence of biallelic mutations of PSMB8 gene. The presence of high levels of IFNγ and of IFNγ related chemokines points to a major pathogenic role of the IFNγ pathway, which appears to be similar to what has been recently reported in CANDLE (Liu et al). The pathogenic role of the variant T74S remains to be elucidated:a potential role is suggested by its presence in a patient with a classical phenotype and with a dysregulation of the IFNγ pathway, taking also into account that this variant is close to the know pathogenic mutation T75M.


Disclosure:

A. Insalaco,
None;

G. Prencipe,
None;

M. Pardeo,
None;

V. Messia,
None;

A. Masotti,
None;

C. de Min,

Novimmune,

3;

C. Bracaglia,
None;

R. Nicolai,
None;

I. Caiello,
None;

F. De Benedetti Sr.,

Novartis, Novimmune, Hoffmann-La Roche, SOBI, AbbVie,

2,

AbbVie Novartis, Novimmune, Hoffmann-La Roche, SOBI ,

5.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/involvement-of-the-ifn-o-pathway-in-a-patient-with-candle-syndrome-carrying-a-novel-variant-of-psmb8-gene/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology